GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Porton Pharma Solutions Ltd (SZSE:300363) » Definitions » Capex-to-Operating-Income

Porton Pharma Solutions (SZSE:300363) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Porton Pharma Solutions Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Porton Pharma Solutions's Capital Expenditure for the three months ended in Mar. 2024 was ¥-180.08 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥-128.27 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Porton Pharma Solutions Capex-to-Operating-Income Historical Data

The historical data trend for Porton Pharma Solutions's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Porton Pharma Solutions Capex-to-Operating-Income Chart

Porton Pharma Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.96 1.22 0.51 3.33

Porton Pharma Solutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 5.19 9.53 - -

Competitive Comparison of Porton Pharma Solutions's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Porton Pharma Solutions's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Porton Pharma Solutions's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Porton Pharma Solutions's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Porton Pharma Solutions's Capex-to-Operating-Income falls into.



Porton Pharma Solutions Capex-to-Operating-Income Calculation

Porton Pharma Solutions's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1129.869) / 339.29
=3.33

Porton Pharma Solutions's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-180.078) / -128.266
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Porton Pharma Solutions  (SZSE:300363) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Porton Pharma Solutions Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Porton Pharma Solutions's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Porton Pharma Solutions (SZSE:300363) Business Description

Traded in Other Exchanges
N/A
Address
Fangzheng Avenue, Porton New Drug Outsourcing Service and R&D Center, Shuitu, Beibei District, Chongqing, CHN, 400714
Porton Pharma Solutions Ltd is a China-based external manufacturing supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies. It is engaged in the process development activities and pilot-scale and commercial-scale manufacturing activities.
Executives
Wang Zhong Neng Executives
Yu Yong Mei Executives
Sun Min Executives
Ji Yao Hui Executives
Ju Nian Feng Directors, executives
Tan Jun Supervisors
Xu Ai Wu Directors, executives
Guo Yong Qing Independent director
Director
Director
Ceng Hui Supervisors
Chen Bei Executives

Porton Pharma Solutions (SZSE:300363) Headlines

No Headlines